Pfizer granted FDA approval for orphan chronic myelogenous leukemia drug

pfizer granted fda approval for orphan drug The FDA has approved Pfizer's bosutinib, an orphan drug for chronic myelogenous leukemia. The drug treats tyrosine kinase, which drives development of abnormal white cells in patients.

Read the full press release from Pfizer here.

“With the approval of tyrosine kinase inhibitors, we are seeing improvements in the treatment of CML based on a better understanding of the molecular basis of the disease,” said Richard Pazdur, director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research. “These improvements have been observed in chronic and accelerated phases of CML.”

Read the full article from FierceBiotech.

For more information on orphan drugs and rare disease, check out the World Orphan Drug Congress USA.

Leave a Reply

Your email address will not be published. Required fields are marked *